Treats insomnia characterized. ANDA 77214, held by Pharmazone. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 77214 (Zolpidem Tartrate), held by Pharmazone, was first approved by FDA on Apr 23, 2007, with 6 approved supplements and 0 published complete response letters.
Zolpidem Tartrate Tablets is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem Tartrate Tablets has been shown to decrease sleep latency for up to 35 days in controlled clinical studies. The clinical trials performed in support of efficacy were 4–5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 23, 2007 | Original application | Approved |
| Zolpidem Tartrate5MG · tablet;oral | Zolpidem Tartrate | Rx |
| Zolpidem Tartrate10MG · tablet;oral | Zolpidem Tartrate | Rx |
| Nov 17, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 1, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 18, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 16, 2010 | Supplement 3Labeling | Approved | None posted |
| Sep 3, 2008 | Supplement 2Labeling | Approved | None posted |
| May 29, 2008 | Supplement 1Labeling | Approved | None posted |
| Apr 23, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters